Dorzolamide: A review

Seminars in Ophthalmology

Volumn 12, Issue 3, 1997, Pages 119-126

  Donohue, Elizabeth K ^a   Wilensky, Jacob T ^b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b University of Illinois Chicago   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; BETAXOLOL; DORZOLAMIDE; PILOCARPINE; SEZOLAMIDE; TIMOLOL;

ALLERGY; ANTIHYPERTENSIVE ACTIVITY; CORNEA EDEMA; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; ENZYME INHIBITION; FATIGUE; GLAUCOMA; HEADACHE; HUMAN; INTRAOCULAR HYPERTENSION; MALAISE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030865889     PISSN: 08820538     EISSN: None     Source Type: Journal    
DOI: 10.3109/08820539709059808     Document Type: Review

References (82)

1. Sears ML, Matsui ML, Murkami M, et al. Localization of Carbonic Anhydrase (CA) mediated aqueous secretion to basolateral membranes of non-pigmented epithelium of ciliary processes. Invest Ophthalmol Vis Sci. 1994;35:1454 (suppl).
2. Wistrand PJ, Schenholm M, Lonnerholm G. Carbonic anhydrase isoenzymes. CA I and CA II in the human eye. Invest Ophthalmol Vis Sci. 1986;27:419-428.
3. Dobbs PC, Epstein DL, Anderson PJ. Identification of isoenzyme C as the principal carbonic anhydrase in the human ciliary processes. Invest Ophthalmol Vis Sci. 1979;18:867-870.
4. Wistrand PJ, Garg LC. Evidence of high-activity C type of carbonic anhydrase in human ciliary processes. Invest Ophthalmol Vis Sci. 1979;18:802-6.
5. Krupin T, Sly WS, Whyte MP, et al. Failure of acetazolamide to decrease intraocular pressure in patients with carbonic anhydrase II deficiency. Am J Ophthalmol. 1985;99:369-399.
6. Sundaram V, Rumbolo P, Grubb J, et al. Carbonic anhydrase II deficiency: Diagnosis and carrier detection using differential enzyme inhibition and inactivation. Am J Hum Genet. 1986;38:125-136.
7. Hageman GS, Zhu XL, Waheed A, et al. Localization of carbonic anhydrase IV in a specific capillary bed of the human eye. Proc Natl Acad Sci U S A. 1991;88(7):2716-2720.
8. Schwam H, Homnick CF, Michelson SR, et al. Identification and partial purification of a sodium dodecyl sulfate resistant carbonic anhydrase activity from the rabbit ciliary process. Invest Ophthalmol Vis Sci. 1993;34:930 (suppl).
9. Sugrue MF, Funk HA, Lazarides E, et al. Evidence for a role of membrane bound carbonic anhydrase in intraocular pressure regulation in rabbits. Invest Ophthalmol Vis Sci. 1994;35:1400 (suppl).
10. Wistrand J: Distribution and function of carbonic anhydrase (CA) isoenzymes in the human eye: Relevance for the design of topical CA inhibitors. Exp Eye Res. 1992;55:S185 (suppl).
11. Maren TH, Wynns GC, Wistrand PJ. Chemical properties of carbonic anhydrase IV, the membrane bound enzyme. Mol Pharmacol 1993;44:901-905.
12. Carter ND, Fryer A, Grant AG, et al. Membrane specific carbonic anhydrase (CAIV) expression in human tissues. Biochem Biol Acta. 1990;1026:113-116.
13. Maren TH, Wynns GC, Wistrand PJ. Properties of carbonic anhydrase (CA) IV, the membrane-bound enzyme in secretory tissues. Invest Ophthalmol Vis Sci. 1993;34:1141 (suppl).
14. Wistrand PJ. Properties of membrane-bound carbonic anhydrase. Ann N YAcad Sci. 1986;429:195-206.
15. Maren TH. Relations between structure and biologic activity of sulfonamides. Annu Rev Pharm Toxicol. 1976; 16:309-327.
16. Hoskins HD, Kass M. Becker-Shaffer's Diagnosis and Therapy of the Glaucomas. St. Louis, MO: Mosby-Year Book; 1989:470-484.
17. Maren TH. Carbonic anhydrase: General perspectives and advances in glaucoma research. Drug Dev Res. 1987;10:255-276.
18. Maren T. The relationship between enzyme inhibition and physiological response in the carbonic anhydrase system. J Pharmacol Exp Ther. 1962;139:140-155.
19. Foss RH. Local application of Diamox: An experimental study of its effect on the intraocular pressure. Am J Ophthalmol. 1955;39:336-339.
20. Gloster J, Perkins ES. Effect of the carbonic anhydrase inhibitor (Diamox) on intraocular pressure of rabbits and cats. Br J Ophthalmol. 1955;39:647-658.
21. Maren TH, Jankowska L, Sanyal G, et al. The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion. Exp Eye Res. 1983;36:457-480.
22. Maren TH, Bar-Ilan A, Caster KC, et al. Ocular pharmacology of methazolamide analogues: Distribution in the eye and effects on pressure after topical application. J Pharmacol Exp Ther. 1987;241:56-63.
23. Lotti VJ, Schmitt CJ, Gautheron PD. Topical ocular hypotensive activity and ocular penetration of dichlorphenamine sodium in rabbits. Graefe's Arch Clin Exp Ophthalmol. 1984:222:13-19.
24. Maren TH, Brechue WF, Bar-Ilan A. Relations among IOP reduction, ocular distribution and pharmacology of the carbonic anhydrase inhibitor ethoxzolamide. Exp Eye Res. 1992;55:73-79.
25. Stein AN, Pinke R, Krupin T, et al. The effect of topically administered carbonic anhydrase inhibitors on aqueous humor dynamics in rabbits. Am J Ophthalmol. 1983;95:222-228.
26. Friedman Z, Allen RC, Raph SM. Topical acetazolamide and methazolamide delivered by contact lenses. Arch Ophthalmol. 1985;103:963-966.
27. Lewis RA, Schoenwald RD, Eller MG, et al. Ethoxzolamide analogue gel: A topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1984:102:1821.
28. Lewis RA, Schoenwald RD, Barfknecht CF, et al. Aminozolamide gel: A trial of a topical carbonic anhydrase inhibitor in ocular hypertension. Arch Ophthalmol. 1986;104:842-844.
29. Kalina PH, Shetlar DJ, Lewis RA, et al. 6-Amino-2-Benzothiazole-Sulfonamide: The effect of a topical carbonic anhydrase inhibitor on aqueous humor formation in the normal human eye. Ophthalmology. 1988;95:772-77.
30. Hunt C, Mallorga P, Michelson S, et al. 3-Substituted Thieno[2,3-b][1,4]thiazine-6-sulfonamides. A novel class of topically active carbonic anhydrase inhibitors. J Med Chem. 1994;37:240-247.
31. Lippa EA, vonDenffer HA, Hofmann HM, et al. Local tolerance and activity of MK-927, a novel topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1988;106:1694-1696.
32. Pfeiffer N, Henneke R, Lippa EA, et al. A single dose of the topical carbonic anhydrase inhibitor MK-927 decreases IOP in patients. Br J Ophthalmol. 1990;74:405-408.
33. Higginbotham EJ, Kass MA, Lippa EA, et al. MK-927: A topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1990; 108: 65-68.
34. Serle JB, Lustgarten JS, Lippa EA, et al. MK-927, A topical carbonic anhydrase inhibitor: Dose response and reproducibility. Arch Ophthalmol. 1990:108:838-841.
35. Lippa EA, Aasved H, Airaksinen PJ, et al. Multiple dose, dose-response relationship for the topical carbonic anhydrase inhibitor MK-927. Arch Ophthalmol. 1991;109:46-49.
36. Mallorga R Reiss ER, Ponticello GS, et al. Binding of the carbonic anhydrase inhibitor MK-927 to ocular pigment. Invest Ophthalmol Vis Sci. 1989;30:445 (suppl).
37. Bron A, Lippa EA, Gunning F, et al. Multiple dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927. Arch Ophthalmol. 1991 ;109: 50-53.
38. Buclin T, Biollaz J, Lippa EL, et al. Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamide during two-week ocular administration to normal subjects. Clin Pharmacol Ther. 1991;49:665-673.
39. Lippa EA, Sherwood M, Laibovitz R, et al. MK-417 vs. timolol: Comparative activity. Invest Ophthalmol Vis Sci. 1990, 31:232 (suppl).
40. Sugrue MF, Waheed A, Sly WS, et al. A study of the in vitro inhibition of human carbonic anhydrase isoenzymes 1, II, and IV. Invest Ophthalmol Vis Sci. 1993;34:930 (suppl).
41. Baldwin JJ, Ponticello GS, Murcko JP, et al. Three dimensional structure of the carbonic anhydrase inhibitor complex derived from human carbonic anhydrase II and the optical isomers of MK-927. Invest Ophthalmol Vis Sci. 1989;30:374 (suppl).
42. Sugrue ME, Mallorga P, Schwam H, et al. A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals. Curr Eye Res. 1990;9(6):607-615.
43. Wang RF, Serie JB, Podos SM, et al. MK-507(L671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol. 1991;109:1297-1299.
44. Wang RF, Serle JB, Podos SM, et al. The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671-152 in glaucomatous monkeys. Arch Ophthalmol. 1990; 108:511-513.
45. Sugrue MF, Mallorga P, Schwam H, et al. The preclinical ocular hypertensive profile of the topical carbonic anhydrase inhibitor L-671-152. Invest Ophthalmol Vis Sci. 1989;30:99 (suppl).
46. Bourgeois H, Bron A, Lippa E, et al. 2% L-671,152: Multiple dose activity BID. Invest Ophthalmol Vis Sci. 1990;31: 233 (suppl).
47. Lippa EA, Schuman JS, Higginbotham EJ, et al. MK-507 versus sezolamide: Comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology. 1991;98(3):308312.
48. Berggren L. Pharmacological and clinical aspects of glaucoma therapy. Acta Ophthalmol Scand. 1990;68:497-507.
49. Donohue EK, Wilensky JT, Nail C, et al. Relative efficacy of dorzolamide by iris color. Ophthalmology. 1995;102: 160 (suppl).
50. Hutzelmann J, Snyder E. Tipping R, et al. Comparison of the IOP lowering effect of 2.0% dorzolamide TID (Trusopt) in patients with light and dark irides. Invest Ophthalmol Vis Sci. 1996;37(3):5062 (suppl).
51. Lippa EA, Carlson LE, Ehinger B, et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1992; 110:495-499.
52. McMahon CD, Laibovitz R. IOP lowering activity of the topical CAI MK-507 at 3%. Invest Ophthalmol Vis Sci. 1991 ;32: 989 (suppl).
53. Sugrue MF, Funk H, Klotzbuecher C. Comparison of the topical carbonic anhydrase inhibitor L-671,152 and timolol in glaucoma monkeys. Invest Ophthalmol Vis Sci. 1990;31:232 (suppl).
54. Strahlman E, Tipping R, Vogel R, and the International Dorzolamide Study Group. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol. 1995;113:1009-1016.
55. Nardin G, Lewis R, Lippa EA, et al. Activity of the topical CAI MK-507 BID when added to timolol BID. Invest Ophthalmol Vis Sci. 1991 ;32:989 (suppl).
56. Sonty S, Viana M. The additive ocular hypotensive effect of topical 2% dorzolamide on glaucomatous eyes on topical beta blocker therapy. Invest Ophthalmol Vis Sci. 1996;37(3):5058 (suppl).
57. Gamero G, Robison M, Harmon H, et al. The duration of action of dorzolamide 2% with concomitant use of a topical beta adrenergic antagonist. Invest Ophthalmol Vis Sci. 1996;37(3): 5067 (suppl).
58. Strahlman EL, Tipping RW, Clineschmidt CM. A controlled clinical trial comparing dorzolamide (MK-507) and pilocarpine as adjunctive therapy to timolol. Ophthalmology 1994;101:129 (suppl).
59. Strahlman E, Vogel R, Tipping R, et al. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology. 1996;103(8):1283-1292.
60. Strahlman E, Barber, Leibovitz R. A comparison of quality of life and patient preference of dorzolamide and pilocarpine as adjunctive therapy to timolol in the treatment of glaucoma. Invest Ophthalmol Vts Sci. 1995:36:967 (suppl).
61. Strahlman ER, Zimmerman K, Campbell C. The safety, ocular tolerability, and IOP lowering effect of a fixed combination of 0.5% timolol and 2.0% MK-507 in normal subjects. Invest Ophthalmol Vis Sei. 1992;33:1122 (suppl).
62. Strahlman ER, Deasy D, Panebianco D. A two-week pilot activity study of a fixed combination of timolol and dorzolamide hydrochloride. Invest Ophthalmol Vis Sci. 1993;34:931 (suppl).
63. Strohmaier K, Snyder E, Adamsons I. Long-term safety and efficacy of Cosopt, a fixed combination of dorzolamide and timolol. Invest Ophthalmol Vis Sci. 1996;37(3):5069 (suppl).
64. Adamsons I, Anderson K, Strohmaier K, et al. Three month results of a clinical trial comparing 0.5% timolol/2.0% MK-507 to concomitant use of 0.5% timolol and 2.0% MK-507. Invest Ophthalmol Vis Sci. 1995;36:735 (suppl).
65. Serie JB, Podos SM, Strahlman ER, et al. Dorzolamide (MK-507) in patients on maximal tolerated medical therapy. Ophthalmology. 1994;101:81 (suppl).
66. Fechtner R, Robison M, Gamero G, et al. A comparison of the efficacy of dorzolamide 2% and oral carbonic anhydrase inhibitors in clinical practice. Invest Ophthalmol Vis Sci. 1996; 37(3):934 (suppl).
67. Maus T, Larsson LI, McLaren J, et al. Comparison of dorzolamide and acetazolamide as suppressers of aqueous humor flow in humans. Arch Ophthalmol. 1997;115:45-49.
68. Rosenberg LF, Krupin T, Ruderman J, et al. Additivity of systemic acetazolamide to topical dorzolamide for reduction of intraocular pressure and aqueous humor production. Ophthalmology. 1996;103:131 (suppl).
69. Sonty S, Viana M. The comparative prophylactic effect of topical dorzolamide and oral acetazolamide to prevent post cataract surgery ocular pressure rise. Invest Ophthalmol Vis Sci. 1996;37:1119 (suppl 3).
70. Helwig W, Conti E, Dutt R. The role of Trusopt in post-cataract intraocular pressure control. Invest Ophthalmol Vis Sei. 1996;37:2713 (suppl 3).
71. Pfeiffer N, Sell E, Winken A, et al. Dorzolamide in acute angle closure glaucoma. Invest Ophthalmol Vis Sci. 1996;37: 5050 (suppl 3).
72. Conroy C, Wynns G, Maren T. Carbonic anhydrase inhibitors (CAI) do not reach the retina by the topical route. Invest Ophthalmol Vis Sci. 1994;35(4):2220 (suppl).
73. Mathur S, Grunwald J, DuPont J. Effects of dorzolamide hydrochloride 2% on the retinal circulation. Invest Ophthalmol Vis Sci. 1996;37(3):S270(suppl).
74. Arend O, Harris A, Martin B. Acute application of dorzolamide increases retina and epipapillary optic nerve head circulation in healthy subjects. Invest Ophthalmol Vis Sci. 1996;37(3):1010(suppl).
75. Donohue E, Wilensky J. Clinical use of Trusopt in infants and children: A case series. Presented at the American Glaucoma Society Meeting, Vancouver, British Colombia, Canada, July 27-August2, 1996.
76. Biollaz L, Munafo A, Buclin T, et al. Whole-blood pharmakokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol. 1995; 45:453-460.
77. Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1993;111:1343-1350.
78. Lucci M, Tinker J, Weiner I, et al. Function of proximal tubule carbonic anhydrase defined by selective inhibition. Am J Physiol. 1983;245:F443-F449.
79. Connor J, Keilani T, Segal R, et al. Pharmacokinetics and safety of dorzolamide (MK-507) in patients with moderate renal impairment. Invest Ophthalmol Vis Sci. 1995;36:3413 (suppl 4).
80. Heijl A, Strahlman E, Sverrisson T, et al. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension. Ophthalmology. 1997;104(1): 137-142.
81. Quinones R, Wilensky J, Viana M, et al. Effect of dorzolamide on corneal thickness in humans. Invest Ophthalmol Vis Sci. 1996;37(3):5046 (suppl).
82. Konowal A, Epstein R, Dennis R, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Invest Ophthalmol Vis Sci. 1996;37(3):79 (suppl).